Biologic Therapeutic Drugs: Technologies and Global Markets

Report Highlights

The market for biologics was valued at $150 billion in 2011 and should reach $163 billion in 2012. Total market value is expected to reach $252 billion in 2017 after increasing at a five-year compound annual growth rate of 9%. 

Report Includes

• An overview of the global market for biologic therapeutic drugs
• Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Coverage of large market segments such as monoclonal antibodies (mAb), therapeutic proteins, and vaccines
• Examination of the competitive environment with a special focus on how new products and technologies are influencing the current standard of care
• Comprehensive profiles of current market leaders, as well as companies with innovative products poised to advance within the forecast period.

Report Scope

Current and projected product forecasts during the forecast period (2012 to 2017) are discussed.  As well, new products approved in 2009 and 2012 by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) and those products expected to be approved within the forecast period are projected within their respective segment.  Figures for 2012 are projected estimates, except where actual results have been reported due to the release timing of the report.  For large markets segments such as mAb, therapeutic proteins and vaccines, specific mechanisms of action are discussed in detail.  For example, the trend of increased use of vascular endothelial growth factor (VEGF) inhibitors as a first-line therapy for multiple disease states such as colorectal cancer and the ophthalmic disease wet age-related macular degeneration (AMD) are discussed.

The report includes analysis of leading and emerging competitors in the current worldwide market.  Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development are analyzed to define their specific product strategies employed.  This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.  The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care.  Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to advance within the forecast period.

Market figures are based on revenues at the manufacturers’ level and are projected at 2012 dollar value.  Inflation is not computed into the projection figures.  Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products, and projected changes in the prevalence, diagnosis, and scripting rates for certain diseases.

Included in this report are forecasts by product, product category and by company from 2009 through 2017.  The study is arranged to offer an overview of the biologics market accompanied by product, company, geography and mechanism of action with forecasts broken down and covered by geographic region or country.  Virtually the entire globe is covered to include prevalence data for each disease subsegment.

Excluded from this report are over-the-counter (OTC) medications and other consumables that do not require a physician’s prescription.

Sales figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change.  Revenue figures do not account for variation in local currencies.

All market share data presented are on a global basis unless specifically noted.

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.